Baidu
map

Am J Clin Nutr:补充维生素D可以降低绝经后乳腺癌风险

2015-10-25 Seven L 译 MedSci原创

有研究表明维生素D可以对乳腺癌发生的发生起保护作用,尤其是雌激素受体阳性的肿瘤,不过目前关于该经验性结果的流行病学研究并没有。研究者进行了一项研究探究绝经后乳腺癌风险和现在或过去维生素D补充情况间关系,以及根据更年期激素疗法(MHT)的使用情况进行分层研究。该研究在1995-2008年间从E3N前瞻性队列研究中纳入了 57,403名绝经后妇女,在长达 581,085 人年的随访过程中,发生率248

有研究表明维生素D可以对乳腺癌的发生起保护作用,尤其是雌激素受体阳性的肿瘤,不过目前并没有关于该经验性结果的流行病学研究。

研究者进行了一项研究探究绝经后乳腺癌风险和现在或过去维生素D补充情况间关系,以及根据更年期激素疗法(MHT)的使用情况进行分层研究。

该研究在1995-2008年间从E3N前瞻性队列研究中纳入了 57,403名绝经后妇女,在长达 581,085 人-年的随访过程中,发生了2482例浸润性乳腺癌。研究者根据1995年、2000年、2002年以及2005年的问卷调查,以及自2004年以来药物使用情况,评估参与者维生素D摄入情况。

研究结果显示,对于绝经后乳腺癌,目前补充维生素D可以降低其风险 (HR: 0.82; 95% CI: 0.69, 0.97),但是对于过去补充维生素D并不会起到保护作用 (HR: 1.10; 95% CI: 0.92, 1.31) (P-homogeneity = 0.02)。

更年期激素疗法(MHT)的使用与否,也会对该联系产生影响。对于现在补充维生素D+使用过MHT的人群:HR: 0.74; 95% CI: 0.60, 0.90;现在补充维生素D但没有使用过MHT的人群:HR: 1.13; 95% CI: 0.89, 1.56;P-homogeneity = 0.02。

该观察研究表明。现在维生素D的补充,尤其是每日补充且补钙,可用降低MHT使用人群的绝经后乳腺癌发生风险。

原始出处:


Cadeau , Fournier A, Mesrine S,et al.Interaction between current vitamin D supplementation and menopausal hormone therapy use on breast cancer risk: evidence from the E3N cohort.Am J Clin Nutr. 2015 Oct;102(4):966-73.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1770239, encodeId=b88b1e702398b, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Dec 30 17:52:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061486, encodeId=a16d2061486c0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Feb 27 03:52:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57143, encodeId=96ed5e14335, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:46:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42052, encodeId=290742052ed, content=维生素反正无大害, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Sat Oct 31 14:18:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257029, encodeId=1a55125e02960, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631501, encodeId=59761631501f1, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41312, encodeId=52114131268, content=依据还不是很充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Oct 26 11:14:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1770239, encodeId=b88b1e702398b, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Dec 30 17:52:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061486, encodeId=a16d2061486c0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Feb 27 03:52:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57143, encodeId=96ed5e14335, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:46:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42052, encodeId=290742052ed, content=维生素反正无大害, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Sat Oct 31 14:18:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257029, encodeId=1a55125e02960, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631501, encodeId=59761631501f1, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41312, encodeId=52114131268, content=依据还不是很充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Oct 26 11:14:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2016-02-27 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=1770239, encodeId=b88b1e702398b, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Dec 30 17:52:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061486, encodeId=a16d2061486c0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Feb 27 03:52:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57143, encodeId=96ed5e14335, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:46:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42052, encodeId=290742052ed, content=维生素反正无大害, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Sat Oct 31 14:18:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257029, encodeId=1a55125e02960, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631501, encodeId=59761631501f1, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41312, encodeId=52114131268, content=依据还不是很充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Oct 26 11:14:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2016-01-13 Lynee劲飞扬

    给力

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1770239, encodeId=b88b1e702398b, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Dec 30 17:52:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061486, encodeId=a16d2061486c0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Feb 27 03:52:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57143, encodeId=96ed5e14335, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:46:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42052, encodeId=290742052ed, content=维生素反正无大害, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Sat Oct 31 14:18:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257029, encodeId=1a55125e02960, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631501, encodeId=59761631501f1, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41312, encodeId=52114131268, content=依据还不是很充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Oct 26 11:14:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2015-10-31 liusanxin

    维生素反正无大害

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1770239, encodeId=b88b1e702398b, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Dec 30 17:52:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061486, encodeId=a16d2061486c0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Feb 27 03:52:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57143, encodeId=96ed5e14335, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:46:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42052, encodeId=290742052ed, content=维生素反正无大害, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Sat Oct 31 14:18:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257029, encodeId=1a55125e02960, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631501, encodeId=59761631501f1, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41312, encodeId=52114131268, content=依据还不是很充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Oct 26 11:14:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1770239, encodeId=b88b1e702398b, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Dec 30 17:52:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061486, encodeId=a16d2061486c0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Feb 27 03:52:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57143, encodeId=96ed5e14335, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:46:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42052, encodeId=290742052ed, content=维生素反正无大害, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Sat Oct 31 14:18:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257029, encodeId=1a55125e02960, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631501, encodeId=59761631501f1, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41312, encodeId=52114131268, content=依据还不是很充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Oct 26 11:14:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2015-10-27 zxxiang
  7. [GetPortalCommentsPageByObjectIdResponse(id=1770239, encodeId=b88b1e702398b, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Dec 30 17:52:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061486, encodeId=a16d2061486c0, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Feb 27 03:52:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57143, encodeId=96ed5e14335, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:46:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42052, encodeId=290742052ed, content=维生素反正无大害, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Sat Oct 31 14:18:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257029, encodeId=1a55125e02960, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631501, encodeId=59761631501f1, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Tue Oct 27 04:52:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41312, encodeId=52114131268, content=依据还不是很充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Oct 26 11:14:00 CST 2015, time=2015-10-26, status=1, ipAttribution=)]
    2015-10-26 lixh1719

    依据还不是很充分

    0

相关资讯

女性肿瘤预防基金聚力公益 为乳腺癌高危人群保驾护航

同济-宜朗乳腺肿瘤预防门诊爱心援助仪式 16日召开的首都国际癌症论坛上,中国抗癌协会秘书长王瑛说,据2012年癌症有关报告显示,我国每年新发癌症病例约337万,死亡约211万。男性当中肺癌发病率最高,女性是乳腺癌。乳腺癌已经成为威胁女性健康的“头号杀手”,恰逢10月份是世界乳腺癌防治月,乳腺癌再度成为公众关注的焦点。 近日,有媒体报道称苏州有一位叫周雪玮的女士,因为不想给家里添加经

JAMA:指南:女性该怎样进行乳腺癌风险筛查?

据美国癌症协会最新发表的乳腺癌指南,女性在40岁以后应每年定时筛查乳腺癌,且应持续到55岁以后。这份新的乳腺癌指南发表在JAMA。自2003年更新乳腺癌预防指南以来,美国癌症协会(ACS)指出,女性患乳腺癌的发病率逐年降低。ACS指出,有罹患乳腺癌风险的女性应从45岁起每年进行乳房x光检查进行乳腺癌风险筛查(也有人认为应该提早进行筛查风险),55岁以上的女性应该隔年进行一次乳房x光检查(也有人认为

Lancet:二磷酸盐可减少乳腺癌骨转移

磷酸盐可以对骨骼的生理产生影响,从而修改转移的过程。研究者为探究二磷酸盐辅助治疗乳腺癌的利和弊,进行了一项荟萃分析。研究者纳入早期乳腺癌患者,随机分为二磷酸盐组和对照组。以复发、远处转移、乳腺癌死亡率作为初始结局指标。以下情况分亚组:远处转移位置(骨或其他)、月经状态 (自然或人工绝经后、非绝经)、二磷酸盐类别(亚甲基氨基二膦酸盐或其他)。研究共纳入18,766名女性,其中18,206 [97%]

Lancet Oncol:Etirinotecan pegol治疗乳腺癌效果分析

乳腺癌患者需要寻找新的方法来对该病进行治疗。Etirinotecan pegol是一种长效的拓扑异构酶I抑制剂,可以延长肿瘤细胞对于SN38(该药的活性成分)的暴露时间,但同时也降低了SN38浓度过高所带来的毒性效应。研究人员意在评估Etirinotecan pegol对局部复发的或转移性乳腺癌患者的治疗效果是否优于传统疗法。在11个国家的135处实验室处进行随机且开放式的,并且是多中心的3期临床

CEBP:不同乳腺癌亚型之间的差异性 或帮助新型疗法的开发

少数民族女性,尤其是非洲裔美国人、西班牙白人和美洲印第安人,往往容易被诊断为恶性乳腺癌,而这些患者不太可能接受推荐的方案进行治疗,因此其更容易因乳腺癌而死亡;此前研究中研究人员阐明了不同阶段疾病及患者死亡率之间的不一致性,但并没有对疾病的亚型进行分析对比。 刊登在国际杂志Cancer Epidemiology,Biomarkers & Prevention的一项研究论文中,来自西雅图Fr

Lancet:早期乳腺癌内分泌治疗——芳香化酶抑制剂 vs 他莫昔芬(Meta)

临床上对于早期乳腺癌患者内分泌治疗的优先选择尚不明确,究竟是选芳香化酶抑制剂还是他莫昔芬。研究者就该问题进行了一项荟萃分析,涉及31,920 名绝经后、雌激素受体阳性的早期乳腺癌患者,随机进行了长达5年的芳香化酶抑制剂 vs 5年的他莫昔芬治疗;5年的芳香化酶抑制剂 vs 2-3年他莫昔芬+随后芳香化酶抑制剂治疗(总共5年时间);2-3年他莫昔芬+随后芳香化酶抑制剂治疗(总共5年时间) vs 5年

Baidu
map
Baidu
map
Baidu
map